Search jobs Twist Bioscience Reports First Quarter Fiscal 2021 Financial Results
SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) #DNA Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the first quarter of fiscal 2021 ended December 31, 2020.
“We reported a strong quarter both for orders and revenue, building a solid foundation for fiscal 2021,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “We see early evidence that our investment in synbio products for our pharmaceutical and biotech customers is beginning to gain traction, and for our NGS tools business, our liquid biopsy customers continue to drive revenue growth. Both our biopharma and DNA data storage teams made progress in advancing technologies, and we strengthened our balance sheet with $324 million
Sustainability and the Synthetic Biology Revolution
Twist Biopharma, a division of Twist Bioscience, provides synthetic antibody libraries and synthetic genes to facilitate the discovery and optimization of antibody drugs. In this image,
a Twist research associate,
Emily Sever, is at work
in the company’s drug
discovery laboratory.
Sustainability and the Synthetic Biology Revolution
Twist Bioscience anticipates that DNA writing technology will help advance precision medicine, curb pollution, conserve energy, and store data more securely and economically
January 8, 2021
Twist Biopharma, a division of Twist Bioscience, provides synthetic antibody libraries and synthetic genes to facilitate the discovery and optimization of antibody drugs. In this image,